An investigation has been launched with the Competition Board decision dated 19.09.2024 and numbered 24-38/897-M on the economic entity comprised of Biota Bitkisel İlaç ve Kozmetik Laboratuarları AŞ, Derma Cos İlaç Medikal ve Kozmetik Sanayii and İç Ticaret AŞ ile Derma-Cos Kozmetik Sanayi Ticaret İthalat ve İhracat Limited Şirketi, active in the pharmacy channel wih the Bioxcin, Nutraxin, Bioder and Biobaby brands and in the supermarket channel with the Bioblas and Restorex brands, in order to determine if it violated Article 4 of the Act no 4054 on the Protection of Competition by maintaining the sale prices of resellers and/or by restricting online sales.